WO1992011034A1 - Agents for potentiating the effects of antitumor agents and combating multiple drug resistance - Google Patents
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance Download PDFInfo
- Publication number
- WO1992011034A1 WO1992011034A1 PCT/GB1991/002248 GB9102248W WO9211034A1 WO 1992011034 A1 WO1992011034 A1 WO 1992011034A1 GB 9102248 W GB9102248 W GB 9102248W WO 9211034 A1 WO9211034 A1 WO 9211034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- phenyl
- substituted
- dihydro
- Prior art date
Links
- 0 CCCC(C[C@@](CC)*=C)N(*=C)C(C)=N Chemical compound CCCC(C[C@@](CC)*=C)N(*=C)C(C)=N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU90626/91A AU665341B2 (en) | 1990-12-18 | 1991-12-17 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
DE69120430T DE69120430D1 (en) | 1990-12-18 | 1991-12-17 | AGENTS FOR REINFORCING THE EFFECT OF ANTITUMORAL AGENTS AND FOR RESISTANCE TO MULTIPLE DRUGS |
EP92901246A EP0563134B1 (en) | 1990-12-18 | 1991-12-17 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
JP4502139A JPH06504772A (en) | 1990-12-18 | 1991-12-17 | Drugs that enhance the efficacy of anticancer drugs and exhibit anti-multidrug resistance |
US08/074,852 US5416091A (en) | 1990-12-18 | 1991-12-17 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909027367A GB9027367D0 (en) | 1990-12-18 | 1990-12-18 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
GB909027402A GB9027402D0 (en) | 1990-12-18 | 1990-12-18 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
GB9027402-8 | 1990-12-18 | ||
GB9027358-2 | 1990-12-18 | ||
GB909027358A GB9027358D0 (en) | 1990-12-18 | 1990-12-18 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
GB9027367-3 | 1990-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992011034A1 true WO1992011034A1 (en) | 1992-07-09 |
Family
ID=27265406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1991/002248 WO1992011034A1 (en) | 1990-12-18 | 1991-12-17 | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
Country Status (8)
Country | Link |
---|---|
US (1) | US5416091A (en) |
EP (1) | EP0563134B1 (en) |
JP (1) | JPH06504772A (en) |
AT (1) | ATE139447T1 (en) |
AU (1) | AU665341B2 (en) |
CA (1) | CA2098198A1 (en) |
DE (1) | DE69120430D1 (en) |
WO (1) | WO1992011034A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010516A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1995010514A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1995010515A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1995015949A1 (en) * | 1993-12-06 | 1995-06-15 | Schering Corporation | Tricyclic derivatives and their use in pharmaceuticals |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
US5516655A (en) * | 1994-04-20 | 1996-05-14 | Eli Lilly And Company | Multiple drug resistance gene of Aureobasidium pullulans |
WO1996030363A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030017A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030362A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996031478A1 (en) * | 1995-04-07 | 1996-10-10 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996031505A1 (en) * | 1995-04-07 | 1996-10-10 | Pharmacopeia, Inc. | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996031111A1 (en) * | 1995-04-07 | 1996-10-10 | Schering Corporation | Tricyclic compounds useful in the treatment of cell proliferative disorders |
US5574173A (en) * | 1993-12-06 | 1996-11-12 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5672611A (en) * | 1995-04-07 | 1997-09-30 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5705352A (en) * | 1995-02-27 | 1998-01-06 | Eli Lilly And Company | Multiple drug resistance gene of Aspergillus fumigatus |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5767113A (en) * | 1995-05-10 | 1998-06-16 | The Salk Institute For Biological Studies | Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance |
US5773214A (en) * | 1995-02-27 | 1998-06-30 | Eli Lilly And Company | Multiple drug resistance gene of aspergillus flavus |
US5801175A (en) * | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US5900421A (en) * | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
WO1999032114A1 (en) * | 1997-12-22 | 1999-07-01 | Schering Corporation | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
US6100274A (en) * | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
US6114346A (en) * | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
WO2000061145A1 (en) * | 1999-04-09 | 2000-10-19 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6242458B1 (en) | 1993-10-15 | 2001-06-05 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6638736B1 (en) | 1998-04-21 | 2003-10-28 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Human K+ ion EAG channels |
US6709676B2 (en) | 1999-12-20 | 2004-03-23 | Schering Corporation | Extended release oral dosage composition |
US6777415B2 (en) | 2000-10-05 | 2004-08-17 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
US6979463B2 (en) | 1999-12-20 | 2005-12-27 | Schering Corporation | Stable extended release oral dosage composition |
US7070968B2 (en) | 1994-02-04 | 2006-07-04 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
EP2420236A3 (en) * | 2007-04-13 | 2012-06-27 | Southern Research Institute | Anti-angiogenic agents |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053811A1 (en) * | 1997-05-27 | 1998-12-03 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
TW522014B (en) * | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
US6703400B2 (en) | 2001-02-23 | 2004-03-09 | Schering Corporation | Methods for treating multidrug resistance |
US20040067992A1 (en) * | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
US20030220376A1 (en) * | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
-
1991
- 1991-12-17 JP JP4502139A patent/JPH06504772A/en active Pending
- 1991-12-17 EP EP92901246A patent/EP0563134B1/en not_active Expired - Lifetime
- 1991-12-17 US US08/074,852 patent/US5416091A/en not_active Expired - Fee Related
- 1991-12-17 WO PCT/GB1991/002248 patent/WO1992011034A1/en active IP Right Grant
- 1991-12-17 DE DE69120430T patent/DE69120430D1/en not_active Expired - Lifetime
- 1991-12-17 AT AT92901246T patent/ATE139447T1/en not_active IP Right Cessation
- 1991-12-17 AU AU90626/91A patent/AU665341B2/en not_active Expired - Fee Related
- 1991-12-17 CA CA002098198A patent/CA2098198A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
Agents and Actions, vol. 18, nos 5-6, 1986, (Basel, CH), L.C. IORIO et al.: "Interaction studies in mice of SCH 29851, a potential non-sedating antihistamine, with commonly used therapeutic agents", pages 485-493, see abstract * |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714609A (en) * | 1993-10-15 | 1998-02-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1995010515A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5807853A (en) * | 1993-10-15 | 1998-09-15 | Schering Corporation | Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases |
US6242458B1 (en) | 1993-10-15 | 2001-06-05 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
AU698960B2 (en) * | 1993-10-15 | 1998-11-12 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US6300338B1 (en) | 1993-10-15 | 2001-10-09 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1995010516A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5977128A (en) * | 1993-10-15 | 1999-11-02 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5728703A (en) * | 1993-10-15 | 1998-03-17 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6492381B1 (en) | 1993-10-15 | 2002-12-10 | Schering Corp. | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
EP1123931A1 (en) * | 1993-10-15 | 2001-08-16 | Schering Corporation | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5696121A (en) * | 1993-10-15 | 1997-12-09 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1995010514A1 (en) * | 1993-10-15 | 1995-04-20 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
US5574173A (en) * | 1993-12-06 | 1996-11-12 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
WO1995015949A1 (en) * | 1993-12-06 | 1995-06-15 | Schering Corporation | Tricyclic derivatives and their use in pharmaceuticals |
US5688805A (en) * | 1993-12-06 | 1997-11-18 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5464840A (en) * | 1993-12-06 | 1995-11-07 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US7838512B2 (en) | 1994-02-04 | 2010-11-23 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US7070968B2 (en) | 1994-02-04 | 2006-07-04 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5516655A (en) * | 1994-04-20 | 1996-05-14 | Eli Lilly And Company | Multiple drug resistance gene of Aureobasidium pullulans |
US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
US7211582B1 (en) | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
US5731319A (en) * | 1994-12-30 | 1998-03-24 | Sepracor Inc. | Methods for treating disorders using descarboethoxyloratadine |
US7214683B1 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
US7214684B2 (en) | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Methods for the treatment of allergic rhinitis |
US5705352A (en) * | 1995-02-27 | 1998-01-06 | Eli Lilly And Company | Multiple drug resistance gene of Aspergillus fumigatus |
US5773214A (en) * | 1995-02-27 | 1998-06-30 | Eli Lilly And Company | Multiple drug resistance gene of aspergillus flavus |
US5958939A (en) * | 1995-03-24 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of a g-protein function and for treatment of proliferative diseases |
US5703090A (en) * | 1995-03-24 | 1997-12-30 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1996030363A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030017A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996030362A1 (en) * | 1995-03-24 | 1996-10-03 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5807852A (en) * | 1995-03-24 | 1998-09-15 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5684013A (en) * | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5700806A (en) * | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5672611A (en) * | 1995-04-07 | 1997-09-30 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5801175A (en) * | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
AU719990B2 (en) * | 1995-04-07 | 2000-05-18 | Pharmacopeia, Inc. | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5712280A (en) * | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1996031505A1 (en) * | 1995-04-07 | 1996-10-10 | Pharmacopeia, Inc. | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
WO1996031111A1 (en) * | 1995-04-07 | 1996-10-10 | Schering Corporation | Tricyclic compounds useful in the treatment of cell proliferative disorders |
US5891872A (en) * | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
US6214827B1 (en) | 1995-04-07 | 2001-04-10 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
WO1996031478A1 (en) * | 1995-04-07 | 1996-10-10 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5767113A (en) * | 1995-05-10 | 1998-06-16 | The Salk Institute For Biological Studies | Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance |
US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6143758A (en) * | 1995-12-22 | 2000-11-07 | Schering Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6214828B1 (en) | 1995-12-22 | 2001-04-10 | Schering Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6054463A (en) * | 1997-02-11 | 2000-04-25 | Sepracor Inc. | Methods for treating dermatitis using descarboethoxyloratadine |
US5962464A (en) * | 1997-02-11 | 1999-10-05 | Sepracor Inc. | Methods and compositions for treating allergic asthma using descarboethoxyloratadine |
US5900421A (en) * | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
US6333333B1 (en) | 1997-12-22 | 2001-12-25 | Schering Corporation | Methods for treating proliferative diseases |
WO1999032114A1 (en) * | 1997-12-22 | 1999-07-01 | Schering Corporation | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
CZ298511B6 (en) * | 1997-12-22 | 2007-10-24 | Schering Corporation | Use of benzocycloheptapyridine compounds in combination with antineoplastic medicaments for preparing a compound medicament intended for treating proliferative diseases |
KR100700907B1 (en) * | 1997-12-22 | 2007-03-29 | 쉐링 코포레이션 | Pharmaceutical composition comprising benzocycloheptapyridine compounds and antineoplastic drugs |
US7314914B2 (en) | 1998-04-21 | 2008-01-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. | Human K+channel polypeptides |
US7364730B2 (en) | 1998-04-21 | 2008-04-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. | Human K+ channel and prognosing applications thereof |
US7129207B2 (en) | 1998-04-21 | 2006-10-31 | Max-Planck-Gesellschaft Zur Forderung Wissenschaften E.V. | Human K+ ion channel and therapeutic applications thereof |
US6638736B1 (en) | 1998-04-21 | 2003-10-28 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Human K+ ion EAG channels |
US7364845B2 (en) | 1998-04-21 | 2008-04-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften, E.V. | Human K+ channel and prognosing applications thereof |
US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
AU783177B2 (en) * | 1999-04-09 | 2005-09-29 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
CN100421661C (en) * | 1999-04-09 | 2008-10-01 | 先灵公司 | Method of inducing cancer cell death and tumor regression |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000061145A1 (en) * | 1999-04-09 | 2000-10-19 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
US6100274A (en) * | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
US6114346A (en) * | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
US6265414B1 (en) | 1999-10-22 | 2001-07-24 | Schering Corporation | Treating sleep disorders using desloratadine |
US6709676B2 (en) | 1999-12-20 | 2004-03-23 | Schering Corporation | Extended release oral dosage composition |
US7618649B2 (en) | 1999-12-20 | 2009-11-17 | Schering Corporation | Extended release oral dosage composition |
US7820199B2 (en) | 1999-12-20 | 2010-10-26 | Schering Corporation | Stable extended release oral dosage composition |
US6979463B2 (en) | 1999-12-20 | 2005-12-27 | Schering Corporation | Stable extended release oral dosage composition |
US8187630B2 (en) | 1999-12-20 | 2012-05-29 | Schering-Plough Corporation | Extended release oral dosage composition |
US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
US7902208B2 (en) | 2000-02-03 | 2011-03-08 | Schering Corporation | Treating allergic and inflammatory conditions |
US6777415B2 (en) | 2000-10-05 | 2004-08-17 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
EP2420236A3 (en) * | 2007-04-13 | 2012-06-27 | Southern Research Institute | Anti-angiogenic agents |
Also Published As
Publication number | Publication date |
---|---|
EP0563134A1 (en) | 1993-10-06 |
EP0563134B1 (en) | 1996-06-19 |
ATE139447T1 (en) | 1996-07-15 |
JPH06504772A (en) | 1994-06-02 |
CA2098198A1 (en) | 1992-06-18 |
AU9062691A (en) | 1992-07-22 |
AU665341B2 (en) | 1996-01-04 |
US5416091A (en) | 1995-05-16 |
DE69120430D1 (en) | 1996-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU665341B2 (en) | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | |
US5114951A (en) | Agents for combating multiple drug resistance | |
EP1339399B1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
US5124338A (en) | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | |
US6693125B2 (en) | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | |
US5104858A (en) | Sensitizing multidrug resistant cells to antitumor agents | |
US5124330A (en) | (E)-ethyl 3-(4-chloro-α-(4-methyl-1-piperazinyl)benzyl)cinnamate used for potentiating the effects of antitumor agents and combating multiple drug resistance | |
AU2002246636A1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
WO1995013813A1 (en) | Aminoanthraquinone derivatives to combat multidrug resistance | |
KR102182946B1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
EP2258371A1 (en) | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia | |
US9364459B2 (en) | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | |
US20100041668A1 (en) | Compositions and methods for treating thrombocytopenia | |
US5208238A (en) | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | |
CN104324025A (en) | Use of Hdac Inhibitors for the Treatment of Myeloma | |
US5124339A (en) | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance | |
US20100008923A1 (en) | Organic Compounds | |
SK285584B6 (en) | Use of 11-(4-piperidilydene)-5H-benzo[5,6]cyclohepta[1,2- b]pyridine compound as a farnesyl protein transferase inhibitor for the manufacture of a medicament for the treatment of proliferative disease | |
KR20040025900A (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
US20050119253A1 (en) | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
HUT75163A (en) | Reversal of multi-drug resistance by tetraarylethylenes | |
KR101318806B1 (en) | Methylphenidate derivatives and uses of them | |
AU691787B2 (en) | Treatment of cancers | |
US20090233973A1 (en) | Epothilone derivatives for the treatment of multiple myeloma | |
AU635581B2 (en) | Cancer treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992901246 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2098198 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08074852 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992901246 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992901246 Country of ref document: EP |